Centessa Pharmaceuticals plc (CNTA)Healthcare | Biotechnology | Altrincham, United Kingdom | NasdaqGS
39.66 USD
+0.13
(0.329%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 39.66 Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:44 p.m. EDT
CNTA is experiencing significant momentum due to the imminent acquisition by Eli Lilly, which has driven the stock price to near its 52-week high. However, the company's fundamentals are weak, with negative earnings and high debt-to-equity ratios. While the short-term outlook is positive due to the acquisition, long-term investors should be cautious given the lack of consistent dividends and weak financial health. The options market shows mixed signals, with both bullish and bearish positions, suggesting potential volatility in the near term. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.142009 |
| AutoARIMA | 0.143843 |
| AutoTheta | 0.143878 |
| AutoETS | 0.143891 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 28.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.027 |
| Excess Kurtosis | -0.80 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 22.469 |
| Revenue per Share | 0.111 |
| Market Cap | 6,133,898,752 |
| Forward P/E | -20.98 |
| Beta | 1.26 |
| Previous Name | Centessa Pharmaceuticals Limited |
| Website | https://centessa.com |
As of April 11, 2026, 2:44 p.m. EDT: Options activity suggests a mixed sentiment. Call options are heavily concentrated around the current price, indicating potential bullish sentiment, while put options show significant interest in lower strikes, suggesting some bearish speculation. The high implied volatility and open interest in both calls and puts indicate uncertainty and possible market volatility in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2534978 |
| Address1 | 1 Ashley Road |
| Address2 | 3rd Floor |
| All Time High | 40.26 |
| All Time Low | 2.885 |
| Ask | 50.67 |
| Ask Size | 2 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 3,039,030 |
| Average Daily Volume3 Month | 2,592,683 |
| Average Volume | 2,592,683 |
| Average Volume10Days | 3,039,030 |
| Beta | 1.26 |
| Bid | 28.44 |
| Bid Size | 2 |
| Book Value | 3.531 |
| City | Altrincham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 39.66 |
| Current Ratio | 8.568 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 39.68 |
| Day Low | 39.4 |
| Debt To Equity | 22.469 |
| Display Name | Centessa Pharmaceuticals |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -207,371,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -28.615 |
| Enterprise To Revenue | 395.593 |
| Enterprise Value | 5,933,895,168 |
| Eps Current Year | -1.72444 |
| Eps Forward | -1.89 |
| Eps Trailing Twelve Months | -1.46 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 29.5094 |
| Fifty Day Average Change | 10.1506 |
| Fifty Day Average Change Percent | 0.34397855 |
| Fifty Two Week Change Percent | 225.34978 |
| Fifty Two Week High | 40.26 |
| Fifty Two Week High Change | -0.5999985 |
| Fifty Two Week High Change Percent | -0.014903093 |
| Fifty Two Week Low | 10.95 |
| Fifty Two Week Low Change | 28.71 |
| Fifty Two Week Low Change Percent | 2.6219177 |
| Fifty Two Week Range | 10.95 - 40.26 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,622,208,600,000 |
| Float Shares | 97,857,337 |
| Forward Eps | -1.89 |
| Forward P E | -20.984127 |
| Free Cashflow | -138,539,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 118 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 15,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00466 |
| Held Percent Institutions | 0.96096003 |
| Implied Shares Outstanding | 154,662,092 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-05-28 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. |
| Long Name | Centessa Pharmaceuticals plc |
| Market | us_market |
| Market Cap | 6,133,898,752 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_704505677 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-16 |
| Net Income To Common | -197,532,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,115,339,117 |
| Number Of Analyst Opinions | 7 |
| Open | 39.58 |
| Operating Cashflow | -193,816,992 |
| Operating Margins | -13.84613 |
| Payout Ratio | 0.0 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 39.66 |
| Post Market Time | 1,776,456,604 |
| Prev Name | Centessa Pharmaceuticals Limited |
| Previous Close | 39.53 |
| Price Eps Current Year | -22.998772 |
| Price Hint | 2 |
| Price To Book | 11.231946 |
| Price To Sales Trailing12 Months | 408.92657 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.266 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.30769 |
| Region | US |
| Regular Market Change | 0.13000107 |
| Regular Market Change Percent | 0.32886687 |
| Regular Market Day High | 39.68 |
| Regular Market Day Low | 39.4 |
| Regular Market Day Range | 39.4 - 39.68 |
| Regular Market Open | 39.58 |
| Regular Market Previous Close | 39.53 |
| Regular Market Price | 39.66 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 3,771,841 |
| Return On Assets | -0.20534 |
| Return On Equity | -0.42553002 |
| Revenue Per Share | 0.111 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 154,662,092 |
| Shares Percent Shares Out | 0.0427 |
| Shares Short | 6,607,633 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 6,279,667 |
| Short Name | Centessa Pharmaceuticals plc |
| Short Percent Of Float | 0.049099997 |
| Short Ratio | 1.85 |
| Source Interval | 15 |
| Symbol | CNTA |
| Target High Price | 62.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 43.57143 |
| Target Median Price | 40.0 |
| Total Cash | 294,580,000 |
| Total Cash Per Share | 1.906 |
| Total Debt | 118,381,000 |
| Total Revenue | 15,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.46 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.773575 |
| Two Hundred Day Average Change | 15.886425 |
| Two Hundred Day Average Change Percent | 0.6682388 |
| Type Disp | Equity |
| Volume | 3,771,841 |
| Website | https://centessa.com |
| Zip | WA14 2DT |